NASDAQ:ABOS Acumen Pharmaceuticals (ABOS) Stock Price, News & Analysis $3.48 +0.07 (+2.05%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$3.40▼$3.5750-Day Range$2.14▼$3.8452-Week Range$1.81▼$7.62Volume445,403 shsAverage Volume394,698 shsMarket Capitalization$209.08 millionP/E RatioN/ADividend YieldN/APrice Target$10.75 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Acumen Pharmaceuticals alerts: Email Address Acumen Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside208.9% Upside$10.75 Price TargetShort InterestBearish3.74% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.79Based on 7 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.13) to ($1.37) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.53 out of 5 starsMedical Sector566th out of 936 stocksBiological Products, Except Diagnostic Industry88th out of 154 stocks 3.5 Analyst's Opinion Consensus RatingAcumen Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAcumen Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.Read more about Acumen Pharmaceuticals' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted3.74% of the float of Acumen Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAcumen Pharmaceuticals has a short interest ratio ("days to cover") of 4.Change versus previous monthShort interest in Acumen Pharmaceuticals has recently increased by 67.61%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAcumen Pharmaceuticals does not currently pay a dividend.Dividend GrowthAcumen Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ABOS. Previous Next 3.8 News and Social Media Coverage News SentimentAcumen Pharmaceuticals has a news sentiment score of 0.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Acumen Pharmaceuticals this week, compared to 1 article on an average week.Search Interest15 people have searched for ABOS on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat Follows3 people have added Acumen Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Acumen Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.10% of the stock of Acumen Pharmaceuticals is held by insiders.Percentage Held by Institutions71.01% of the stock of Acumen Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Acumen Pharmaceuticals' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Acumen Pharmaceuticals are expected to decrease in the coming year, from ($1.13) to ($1.37) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Acumen Pharmaceuticals is -3.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Acumen Pharmaceuticals is -3.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAcumen Pharmaceuticals has a P/B Ratio of 0.75. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Acumen Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all $20,000 of his wife's 401k into shares of just ONE stock. Everyone on Wall Street said he was crazy. But a year later, that $20,000 in his wife's account was worth $120,000. Today, he says: "If you thought the dot-com mania was intense, what's about to happen in the coming weeks could be even crazier and could open up a new window of opportunity for 500%-plus gains."Click here now to watch this exclusive interview About Acumen Pharmaceuticals Stock (NASDAQ:ABOS)Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.Read More ABOS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ABOS Stock News HeadlinesJuly 27 at 6:20 AM | americanbankingnews.comAcumen Pharmaceuticals (NASDAQ:ABOS) Lifted to Strong-Buy at CitigroupJuly 27 at 3:32 AM | americanbankingnews.comAcumen Pharmaceuticals (NASDAQ:ABOS) Coverage Initiated by Analysts at CitigroupJuly 27, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.July 26 at 2:47 PM | msn.comCitigroup Initiates Coverage of Acumen Pharmaceuticals (ABOS) with Buy RecommendationJuly 26 at 2:16 AM | americanbankingnews.comShort Interest in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Grows By 67.6%May 16, 2024 | markets.businessinsider.comBuy Rating Justified: Acumen Pharmaceuticals’ Promising Position in Alzheimer’s Treatment MarketMay 16, 2024 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Fate Therapeutics (FATE), Acumen Pharmaceuticals (ABOS) and DENTSPLY SIRONA (XRAY)May 15, 2024 | finance.yahoo.comQ1 2024 Acumen Pharmaceuticals Inc Earnings CallJuly 27, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.May 15, 2024 | finance.yahoo.comAcumen Pharmaceuticals Inc (ABOS) (Q1 2024) Earnings Call Transcript Highlights: Strategic ...May 14, 2024 | investorplace.comABOS Stock Earnings: Acumen Pharmaceuticals Beats EPS for Q1 2024May 14, 2024 | msn.comAcumen Pharmaceuticals GAAP EPS of -$0.25May 14, 2024 | globenewswire.comAcumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business HighlightsMay 14, 2024 | markets.businessinsider.comOptimistic Buy Rating for Acumen Pharmaceuticals Based on Strategic Alzheimer’s Treatment Approach and Promising Clinical ProspectsMay 13, 2024 | globenewswire.comAcumen Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor ConferenceMay 8, 2024 | globenewswire.comAcumen Pharmaceuticals to Participate in the 2024 Bank of America Healthcare ConferenceMay 8, 2024 | finance.yahoo.comAcumen Pharmaceuticals Announces First Patient Dosed in ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer’s DiseaseMay 8, 2024 | globenewswire.comAcumen Pharmaceuticals Announces First Patient Dosed in ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer's DiseaseSee More Headlines Receive ABOS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Acumen Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/20/2024Today7/26/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ABOS CUSIPN/A CIK1576885 Webwww.acumenpharm.com Phone434-297-1000FaxN/AEmployees20Year FoundedN/APrice Target and Rating Average Stock Price Target$10.75 High Stock Price Target$15.00 Low Stock Price Target$7.00 Potential Upside/Downside+208.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.06) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-52,370,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-22.88% Return on Assets-20.82% Debt Debt-to-Equity Ratio0.12 Current Ratio30.20 Quick Ratio30.20 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.61 per share Price / Book0.75Miscellaneous Outstanding Shares60,080,000Free Float55,814,000Market Cap$209.08 million OptionableOptionable Beta0.10 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesMr. Daniel J. O'Connell M.B.A. (Age 53)CEO & Director Comp: $901.2kMr. Matt ZugaCFO & Chief Business OfficerMr. Derek M. Meisner Esq. (Age 53)J.D., Chief Legal Officer & Corporate Secretary Comp: $240.17kDr. James Doherty Ph.D. (Age 56)President & Chief Development Officer Dr. Grant A. Krafft Ph.D.Co-FounderDr. Caleb E. Finch Ph.D.Co-FounderDr. William L. Klein Ph.D.Co-FounderMr. Russell Barton M.S. (Age 65)Chief Operating Officer Comp: $223.68kMs. Kelly CarranzaVice President, Finance & Accounting and Corporate ControllerMs. Alex Braun M.B.A.VP & Head of Investor RelationsMore ExecutivesKey CompetitorsChiasmaNASDAQ:CHMABiomea FusionNASDAQ:BMEAEpizymeNASDAQ:EPZMAthira PharmaNASDAQ:ATHAParatek PharmaceuticalsNASDAQ:PRTKView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 126,422 shares on 7/26/2024Ownership: 0.210%Gladius Capital Management LPBought 10,939 shares on 7/19/2024Ownership: 0.018%Ikarian Capital LLCSold 48,830 shares on 5/17/2024Ownership: 0.443%Price T Rowe Associates Inc. MDBought 1,098,276 shares on 5/15/2024Ownership: 1.828%Vanguard Group Inc.Sold 174,494 shares on 5/10/2024Ownership: 2.771%View All Insider TransactionsView All Institutional Transactions ABOS Stock Analysis - Frequently Asked Questions How have ABOS shares performed this year? Acumen Pharmaceuticals' stock was trading at $3.84 at the beginning of the year. Since then, ABOS shares have decreased by 9.4% and is now trading at $3.48. View the best growth stocks for 2024 here. How were Acumen Pharmaceuticals' earnings last quarter? Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) issued its earnings results on Monday, May, 20th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.23) by $0.02. When did Acumen Pharmaceuticals IPO? Acumen Pharmaceuticals (ABOS) raised $125 million in an initial public offering on Thursday, July 1st 2021. The company issued 8,333,333 shares at a price of $14.00-$16.00 per share. Who are Acumen Pharmaceuticals' major shareholders? Top institutional shareholders of Acumen Pharmaceuticals include Bank of New York Mellon Corp (0.21%), Gladius Capital Management LP (0.02%) and Concourse Financial Group Securities Inc.. Insiders that own company stock include Ra Capital Management, LP, Daniel Joseph Oconnell, Matt Zuga, Derek M Meisner, Russell Barton and Jeffrey L Ives. View institutional ownership trends. How do I buy shares of Acumen Pharmaceuticals? Shares of ABOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ABOS) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredThe #1 Crypto for 2024 (3 Cent Coin)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acumen Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acumen Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ABOS Stock Alerts